Copyright © 2019. Inderes Oy. All rights reserved.

BBS

Analyst

Latest insider trading

Net impact profile

Stock release
24.2.
2021

Financial statement release on 24 February 2021 at 7:15 p.m. (CET)

BBS- Bioactive Bone Substitutes Plc's (“BBS”, “the Company”) Financial Statements Review 1.1.-31.12.2020 (unaudited)

Year 2020 in brief (Reference period 2019)

Stock release
1.2.
2021

BBS-Bioactive Bone Substitutes Plc, Company Announcement on 1 February 2021 at 3:35 pm (UTC +2:00)

MSc. (Tech) Liisa Hukka from Talenom Plc. has been appointed chief financial officer (CFO) of BBS-Bioactive Bone Substitutes PlC (”BBS”, ”the Company”). Hukka will take up her position on 1 February, 2021, when the Company’s current CFO Hannu Säynäjäkangas retires. Hukka works on BBS’ Management Team and reports to the CEO.  

Stock release
11.1.
2021

Management of BBS-Bioactive Bone Substitutes Plc (”BBS”, ”the Company”) estimates that the Company will receive the CE marking for the ARTEBONE® product designed to heal bone fractures and damages during 2021. The obtaining of the CE marking will be delayed from the previous schedule about 9 months and will cause the additional expenses of approximately EUR 300.000. The Company intends to submit the application for processing in approximately April.

Stock release
23.12.
2020

The release of BBS-Bioactive Bone Substitutes' financial calendar and Annual General Meeting in 2021 published by BBS-Bioactive Bone Substitutes Plc on 21.12.2020 at 16:30 CET has been corrected. A clause in accordance with the Market Abuse Regulation has been removed from the release. The corrected release is in entirety below.

BBS-Bioactive Bone Substitutes' financial calendar and Annual General Meeting in 2021

During the year 2021, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows: 

Stock release
21.12.
2020

During the year 2021, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows: 

- Financial Statements Release for the year 2020    Wed, 24 February 2021  

- Half-year financial report January-June 2021        Wed, 25 August 2021        


The Annual Report for the year 2020 will be published on the week 13/2021. 

The Annual General Meeting is planned to be held on Wednesday, 28 April 2021. The Board of Directors of BBS Plc will convene the meeting at a later date.  

Stock release
8.12.
2020

On 9 November 2020 at 8:45 am BBS-Bioactive Bone Substitutes Plc (”BBS”, ”the Company”) published an announcement concerning the acceptance of all claims of Company’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” in the USA.  This information has proved to be  incorrect due to misunderstanding in the correspondence with the patent office.  

Stock release
9.11.
2020

BBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” has now been accepted in the USA. Earlier in spring (7.4.2020) we announced the acceptance of the same patent concerning the product. Now the ARTEBONE® product and its unique component, bone protein extract, are protected by patents around all major market areas globally.

Stock release
31.8.
2020

Correction to the regulatory release of BBS-Bioactive Bone Substitutes Plc published on 31.8.2020 at 12:15 CET

The release of interim report published by BBS-Bioactive Bone Substitutes Plc on 31.8.2020 at 12:15 CET has been supplemented. A clause in accordance with the Market Abuse Regulation, contact information and a brief description of the company have been added to the release. In additionally, Finnish and English versions have been unified. The corrected release is in entirety below.

Stock release
31.8.
2020

BBS-Bioactive Bone Substitutes Plc (BBS) Interim Report 1.1.-30.6.2020 (unaudited)

January-June shortly (comparison season 1-6/2019)

BBS

English translation unavailable for BBS.
BBS-Bioactive Bone Substitutes